Company Overview
| Stock Name | Keymed Bio-B |
|---|---|
| Stock Code | 02162 |
| Company Full Name | To be extracted |
| Industry | Healthcare |
| Principal Activities | 專注於自主發現及開發自體免疫及腫瘤治療領域的創新生物療法,核心產品CM310(IL-4Rα抗體)用於治療多種過敏性疾病,管線包括八種候選藥物,其中五種為臨床階段候選藥物。 |
| Listing Date | 2021-07-08 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | 18A生物科技 |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 四川省成都天府國際生物城生物城中路18號D2棟 |
| Business Address (Hong Kong) | 香港金鐘道力寶中心2座1701室 |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | keymedbio.com |
| Share Registrar | 香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | Mechanism A |
|---|---|
| Offer Price | HK$ 53.30 / shares |
| Offer Price Range | Final offer price only, no range |
| Lot Size | 500 shares |
| Entry Threshold | HK$ 26,650 |
| Par Value | To be extracted |
| Offer Period | 2021-06-25 to 2021-06-30 |
| Global Offering Shares | 58,264,500 shares |
| HK Public Offer Shares (Initial) | 5,827,000 shares (10.0%) |
| Public Offer Lots (Initial) | 11,654lots (Pool A5,827lots,Pool B5,827lots) |
| International Placing Shares (Initial) | 52,437,500 shares (90.0%) |
| Offer Ratio | ~10.0% |
| Total Shares Post-IPO | 270,996,066 shares |
| Greenshoe (Over-allotment Option) | Yes |
| Stabilizing Manager (Greenshoe) | To be extracted |
| Cornerstone Share | 47.5% |
| Clawback Tiers | To be extracted |
| Reallocation Option | Yes |
| Total Global Offering Size | HK$ 3,105,497,850 |
Subscription Tiers
Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.
Pool A
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1 lots | 500 | HK$ 26,650 |
| 2 lots | 1,000 | HK$ 53,300 |
| 3 lots | 1,500 | HK$ 79,950 |
| 4 lots | 2,000 | HK$ 106,600 |
| 5 lots | 2,500 | HK$ 133,250 |
| 6 lots | 3,000 | HK$ 159,900 |
| 7 lots | 3,500 | HK$ 186,550 |
| 8 lots | 4,000 | HK$ 213,200 |
| 9 lots | 4,500 | HK$ 239,850 |
| 10 lots | 5,000 | HK$ 266,500 |
| 12 lots | 6,000 | HK$ 319,800 |
| 14 lots | 7,000 | HK$ 373,100 |
| 16 lots | 8,000 | HK$ 426,400 |
| 18 lots | 9,000 | HK$ 479,700 |
| 20 lots | 10,000 | HK$ 533,000 |
| 30 lots | 15,000 | HK$ 799,500 |
| 40 lots | 20,000 | HK$ 1,066,000 |
| 50 lots | 25,000 | HK$ 1,332,500 |
| 60 lots | 30,000 | HK$ 1,599,000 |
| 70 lots | 35,000 | HK$ 1,865,500 |
| 80 lots | 40,000 | HK$ 2,132,000 |
| 90 lots | 45,000 | HK$ 2,398,500 |
| 100 lots | 50,000 | HK$ 2,665,000 |
| 120 lots | 60,000 | HK$ 3,198,000 |
| 140 lots | 70,000 | HK$ 3,731,000 |
| 160 lots | 80,000 | HK$ 4,264,000 |
| 180 lots | 90,000 | HK$ 4,797,000 |
Pool B
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 200 lots | 100,000 | HK$ 5,330,000 |
| 300 lots | 150,000 | HK$ 7,995,000 |
| 400 lots | 200,000 | HK$ 10,660,000 |
| 500 lots | 250,000 | HK$ 13,325,000 |
| 600 lots | 300,000 | HK$ 15,990,000 |
| 700 lots | 350,000 | HK$ 18,655,000 |
| 800 lots | 400,000 | HK$ 21,320,000 |
| 900 lots | 450,000 | HK$ 23,985,000 |
| 1,000 lots | 500,000 | HK$ 26,650,000 |
| 1,200 lots | 600,000 | HK$ 31,980,000 |
| 1,400 lots | 700,000 | HK$ 37,310,000 |
| 1,600 lots | 800,000 | HK$ 42,640,000 |
| 1,800 lots | 900,000 | HK$ 47,970,000 |
| 2,000 lots | 1,000,000 | HK$ 53,300,000 |
| 3,000 lots | 1,500,000 | HK$ 79,950,000 |
| 4,000 lots | 2,000,000 | HK$ 106,600,000 |
| 5,000 lots | 2,500,000 | HK$ 133,250,000 |
| 5,827 lots | 2,913,500 | HK$ 155,289,550 |
Stock Connect Inclusion Analysis
| Avg Daily HK Mkt Cap | HK$ 20.42B |
|---|---|
| Analysis Result | Already included in Stock Connect (both) |
Valuation & Financials
| Market Cap (at Offer Price) | HK$ 14,444,090,317 |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | 不适用(公司处于亏损状态) |
| Profit/Loss Status | 亏损人民币818.8百万元 |
| Period-End Cash Balance | 人民币199.4百万元 |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
Financial Data
Unit:
'000
RMB
Income Statement
| Item | 2019 | 2020 |
|---|---|---|
| Revenue | 15,645 | 41,190 |
| Administrative expenses | -15,158 | -21,548 |
| Net finance costs | -5,677 | -14,309 |
| Profit before tax | -167,512 | -818,848 |
| Income tax expense | 0 | 0 |
| Profit for the year | -167,512 | -818,848 |
| Profit attributable to owners | -167,512 | -818,583 |
Balance Sheet
| Item | 2019 | 2020 |
|---|---|---|
| Cash and cash equivalents | 432,608 | 199,409 |
| Inventories | 3,306 | 6,846 |
| Total current assets | 518,405 | 380,917 |
| Total assets | 658,578 | 529,945 |
| Total current liabilities | 71,590 | 80,240 |
| Total liabilities | 934,533 | 1,624,748 |
| Total equity | -275,955 | -1,094,803 |
| Equity attributable to owners | -275,955 | -1,094,538 |
Cash Flow Statement
| Item | 2019 | 2020 |
|---|---|---|
| Net cash from operating activities | -68,379 | -119,361 |
| Net cash from investing activities | -58,020 | -113,067 |
| Net cash from financing activities | 505,066 | 7,397 |
| Net increase in cash | 378,667 | -225,031 |
| Depreciation of PP&E | 8,136 | 13,894 |
| Depreciation of right-of-use assets | 4,163 | 5,079 |
| Amortisation of intangible assets | 0 | 19 |
| Purchase of PP&E | -62,264 | -19,806 |
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
| First Day Close | HK$ 68.0 |
|---|---|
| First Day Open | HK$ 78.0 |
| First Day Change | 27.58% |
| First Day Volume | 42544600.0 |
| First Day Turnover | 3004370000.0 |
| Use of Proceeds | 1、約60%,或1765.20百萬港元,于未來三至五年內,將主要用于核心及主要產品的研發及商業化;
2、約15%,或441.30百萬港元,將用于我們其他在研產品的臨床前評估及臨床開發;
3、約15%,或441.30百萬港元,將用于我們新生產及研發設施的租賃付款,及購買機械及設備;
4、約10%,或294.20百萬港元將用于我們的一般企業及營運資金用途。 |
Underwriting Syndicate
Joint Sponsors (3)
Overall Coordinators (3)
Joint Bookrunners (4)
Joint Lead Managers (4)
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | Aranda Investments Pte. Ltd. | 116,433,850 HKD | — | 3.75% | — | 6 months | 2022-01-08 |
| 2 | Boyu Capital Opportunities Master Fund | 77,631,450 HKD | — | 2.50% | — | 6 months | 2022-01-08 |
| 3 | Double Joy Ventures Limited | 77,631,450 HKD | — | 2.50% | — | 6 months | 2022-01-08 |
| 4 | Hillhouse Funds | 116,433,850 HKD | — | 3.75% | — | 6 months | 2022-01-08 |
| 5 | Hudson Bay Master Fund LTD | 38,802,400 HKD | — | 1.25% | — | 6 months | 2022-01-08 |
| 6 | Invesco Advisers, Inc. | 310,525,800 HKD | — | 10.00% | — | 6 months | 2022-01-08 |
| 7 | Janchor Partners Pan-Asian Master Fund | 38,802,400 HKD | — | 1.25% | — | 6 months | 2022-01-08 |
| 8 | Lake Bleu Prime Healthcare Master Fund Limited | 77,631,450 HKD | — | 2.50% | — | 6 months | 2022-01-08 |
| 9 | LAV Fund VI | 77,631,450 HKD | — | 2.50% | — | 6 months | 2022-01-08 |
| 10 | Octagon Investments Master Fund LP | 38,802,400 HKD | — | 1.25% | — | 6 months | 2022-01-08 |
| 11 | Sage Partners Master Fund | 38,802,400 HKD | — | 1.25% | — | 6 months | 2022-01-08 |
| 12 | Springhill Master Fund Limited | 38,802,400 HKD | — | 1.25% | — | 6 months | 2022-01-08 |
| 13 | UBS Asset Management (Singapore) Ltd. | 310,525,800 HKD | — | 10.00% | — | 6 months | 2022-01-08 |
| 14 | Yi Fang Da Sirius Inv. Limited | 38,802,400 HKD | — | 1.25% | — | 6 months | 2022-01-08 |
| 15 | 佳曦控股有限公司 | 77,631,450 HKD | — | 2.50% | — | 6 months | 2022-01-08 |
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | Bo CHEN | — |
| Company Secretary | 張延榮、王承鏱 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 控股股東為Moonshot(由陳博士控制),緊隨全球發售後持股28.71%;高瓴資本管理有限公司通過HH KNY Holdings Limited持股9.56%;Eagle Hero持股6.63%。 |
|---|




